BR112022017382A2 - Composto, composição farmacêutica, uso do composto, e, métodos para tratar ou prevenir uma doença relacionada a ep4 e para tratar uma doença selecionada a partir de uma doença inflamatória, uma dor, um câncer, uma doença metabólica e uma doença do sistema urinário - Google Patents

Composto, composição farmacêutica, uso do composto, e, métodos para tratar ou prevenir uma doença relacionada a ep4 e para tratar uma doença selecionada a partir de uma doença inflamatória, uma dor, um câncer, uma doença metabólica e uma doença do sistema urinário

Info

Publication number
BR112022017382A2
BR112022017382A2 BR112022017382A BR112022017382A BR112022017382A2 BR 112022017382 A2 BR112022017382 A2 BR 112022017382A2 BR 112022017382 A BR112022017382 A BR 112022017382A BR 112022017382 A BR112022017382 A BR 112022017382A BR 112022017382 A2 BR112022017382 A2 BR 112022017382A2
Authority
BR
Brazil
Prior art keywords
disease
compound
treat
alkyl
pain
Prior art date
Application number
BR112022017382A
Other languages
English (en)
Inventor
Zhang Xuejun
Zang Yang
Li Lie
Shen Jie
Liu Zhe
Chang Shaohua
Wang Yonggang
Original Assignee
Wuhan Humanwell Innovative Drug Res And Development Center Limited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Humanwell Innovative Drug Res And Development Center Limited Company filed Critical Wuhan Humanwell Innovative Drug Res And Development Center Limited Company
Publication of BR112022017382A2 publication Critical patent/BR112022017382A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, USO DO COMPOSTO, E, MÉTODOS PARA TRATAR OU PREVENIR UMA DOENÇA RELACIONADA A EP4 E PARA TRATAR UMA DOENÇA SELECIONADA A PARTIR DE UMA DOENÇA INFLAMATÓRIA, UMA DOR, UM CÂNCER, UMA DOENÇA METABÓLICA E UMA DOENÇA DO SISTEMA URINÁRIO. A presente invenção refere-se a um composto capaz de antagonizar efetivamente EP4, que é um composto representado pela Fórmula I, ou um tautômero, um estereoisômero, um hidrato, um solvato, um sal farmaceuticamente aceitável ou um pró-fármaco do composto representado pela Fórmula I. R1 é selecionado a partir de -CH3, -CHF2 e -CF3; R2 é selecionado a partir de alquila C2-C6, cicloalquila C3-C6 , alquila C2-C6 halogenada e cicloalquila C3-C6 halogenada; R3 é selecionado a partir de hidrogênio, halogênio, alquila C1-C2 e alquila C1-C2 fluorada; R4 é selecionado a partir de hidrogênio, halogênio, alquila C1-C6 , alcoxila C1-C6 , alquila C1-C6 halogenada e alcóxi C1-C6 halogenado.
BR112022017382A 2020-03-04 2021-03-04 Composto, composição farmacêutica, uso do composto, e, métodos para tratar ou prevenir uma doença relacionada a ep4 e para tratar uma doença selecionada a partir de uma doença inflamatória, uma dor, um câncer, uma doença metabólica e uma doença do sistema urinário BR112022017382A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010144983 2020-03-04
PCT/CN2021/079073 WO2021175283A1 (zh) 2020-03-04 2021-03-04 新型ep4拮抗剂的合成及其在癌症和炎症中的用途

Publications (1)

Publication Number Publication Date
BR112022017382A2 true BR112022017382A2 (pt) 2022-11-29

Family

ID=77524867

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017382A BR112022017382A2 (pt) 2020-03-04 2021-03-04 Composto, composição farmacêutica, uso do composto, e, métodos para tratar ou prevenir uma doença relacionada a ep4 e para tratar uma doença selecionada a partir de uma doença inflamatória, uma dor, um câncer, uma doença metabólica e uma doença do sistema urinário

Country Status (10)

Country Link
US (1) US20230125494A1 (pt)
EP (1) EP4116291A4 (pt)
JP (1) JP7446460B2 (pt)
KR (1) KR20220143062A (pt)
CN (1) CN113354585A (pt)
AU (1) AU2021229414B2 (pt)
BR (1) BR112022017382A2 (pt)
CA (1) CA3170288A1 (pt)
IL (1) IL296007A (pt)
WO (1) WO2021175283A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116801879A (zh) * 2021-01-28 2023-09-22 深圳众格生物科技有限公司 吡唑酰胺衍生物及其制备方法和应用
KR20240042482A (ko) * 2021-09-03 2024-04-02 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 Ep4 길항제 화합물, 이의 염, 다형체 및 용도
CN114380682A (zh) * 2021-10-27 2022-04-22 上海毕得医药科技股份有限公司 一种2,3-二氟-4-甲氧基苯乙酸合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2576516T3 (pl) 2010-06-03 2015-06-30 Bayer Ip Gmbh N-[(het)aryloetylo)]pirazolo(tio)karboksyamidy i ich analogi heteropodstawione
KR101911105B1 (ko) * 2010-09-21 2018-10-23 에자이 알앤드디 매니지먼트 가부시키가이샤 제약 조성물
MA39906A (fr) * 2014-05-23 2017-03-01 Eisai R&D Man Co Ltd Polythérapies pour le traitement du cancer

Also Published As

Publication number Publication date
CA3170288A1 (en) 2021-09-10
IL296007A (en) 2022-10-01
AU2021229414A1 (en) 2022-10-20
KR20220143062A (ko) 2022-10-24
JP7446460B2 (ja) 2024-03-08
JP2023516714A (ja) 2023-04-20
CN113354585A (zh) 2021-09-07
EP4116291A4 (en) 2024-03-06
US20230125494A1 (en) 2023-04-27
AU2021229414B2 (en) 2023-07-06
WO2021175283A1 (zh) 2021-09-10
EP4116291A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
BR112022017382A2 (pt) Composto, composição farmacêutica, uso do composto, e, métodos para tratar ou prevenir uma doença relacionada a ep4 e para tratar uma doença selecionada a partir de uma doença inflamatória, uma dor, um câncer, uma doença metabólica e uma doença do sistema urinário
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
AR063680A1 (es) Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5.
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
AR057531A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina y composicion farmaceutica
PH12015502675A1 (en) Cycloaklane derivative
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
MX2018012711A (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
RU2018121834A (ru) Новое соединение бифенила или его соль
AR061567A1 (es) Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos
PE20240765A1 (es) Compuestos para la inhibicion de nlrp3 y usos de estos
AR077292A1 (es) Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas
BR112017017529A2 (pt) derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo
AR067599A1 (es) Derivados de indazol sustituido activos como inhibidores de quinasa
CA3180846A1 (en) Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
JP2009541223A5 (pt)
EA200900593A1 (ru) Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
NZ592238A (en) Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivatives
BR112015026478A2 (pt) derivados de dolastatina 10 e auristatinas
NO20081582L (no) Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer
PH12020552244A1 (en) Heterocyclic compounds as trk inhibitors
WO2007134827A8 (en) 5-phenyl-thiaz0l-2-yl-urea derivatives and use as pi3 kinase inhibitors
MX2019010096A (es) Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.